Annals of Neurology 2013. ePub ahead of print.
Susan Searles Nielsen PhD,*, Gary M. Franklin MD, MPH, W. T. Longstreth Jr, MD, MPH, Phillip D. Swanson MD, PhD, Harvey Checkoway PhD
Objective
To test whether risk of Parkinson disease (PD) is associated with consumption of nicotine-containing edibles from the same botanical family as tobacco, Solanaceae, including peppers, tomatoes, and potatoes.
Methods
In a population-based study with 490 newly diagnosed idiopathic PD cases diagnosed during 1992–2008 at the University of Washington Neurology Clinic or Group Health Cooperative in western Washington State and 644 unrelated, neurologically normal controls, we examined whether PD was associated with self-reported typical frequency of consumption of peppers, tomatoes, tomato juice, and potatoes during adulthood, while adjusting for consumption of other vegetables, age, sex, race/ethnicity, tobacco use, and caffeine.
Results
PD was inversely associated with consumption of all edible Solanaceae combined (relative risk [RR] = 0.81, 95% confidence interval [CI] = 0.65–1.01 per time per day), but not consumption of all other vegetables combined (RR = 1.00, 95% CI = 0.92–1.10). The trend strengthened when we weighted edible Solanaceae by nicotine concentration (ptrend = 0.004). An inverse association was also evident for peppers specifically (ptrend = 0.005). The potentially protective effect of edible Solanaceae largely occurred in men and women who had never used tobacco or who had smoked cigarettes <10 years.
Interpretation
Dietary nicotine or other constituents of tobacco and peppers may reduce PD risk. However, confirmation and extension of these findings are needed to strengthen causal inferences that could suggest possible dietary or pharmaceutical interventions for PD prevention. Ann Neurol 2013
Welcome to the blog for the PREDICT-PD project. We are working to understand the risk factors for Parkinson's Disease and blogging about advances made in prediction and early detection of the disease.
Subscribe to:
Post Comments (Atom)
Mild Parkinsonian Signs in a Community Population
One question that many of the PREDICT-PD participants ask me is “I am slower than I used to be, does it mean that I am getting Parkinson’...
-
What motivates Parkinson's disease patients to enter clinical trials? Valadas A, Coelho M, Mestre T et al. Parkinsonism Relat Disord....
-
Motor and non-motor correlates of olfactory dysfunction in Parkinson's disease. Berendse HW , Roos DS , Raijmakers P , Doty RL . J...
An antiparkinson, or antiparkinsonian, is a type of drug which is intended to treat and relieve the symptoms of Parkinson's disease (PD) or Parkinsonism. Most of these agents act by either increasing dopamine activity or reducing acetylcholine activity in the central nervous system (CNS).
ReplyDelete